Company Profile

 

Outline of company

Company name
JUZEN CHEMICAL CORPORATION
Establishment
November 16, 1950
Paid capital
65 Million YEN
Management
Daisuke Hirota, President and Chief Executive Officer
Shogo Soma, Managing Director
Masaki Shinoda, Director
Masakazu Himeno, Director
Business field
Pharmaceuticals Segment
- Contract manufacturing of Active Pharmaceutical
- Ingredients and the key intermediates
- Contract manufacturing as trial production of investigational
- Active Pharmaceutical Ingredients and so forth
- CMC Solution Services
Fine Chemicals Segment
- Contract manufacturing of special intermediates
- Production of Malonic acid and Pyrimidine derivatives
Locations
Head office
Head office
1-10, Kiba-machi, Toyama-city, Toyama, 930-0806, JapanMAP
TEL: +81-76-433-1111, FAX: +81-76-432-1165
Tokyo branch
9F Yamate Building No.3
2-7-13, Uchikanda, Chiyoda-ku, Tokyo, 101-0047 MAP
TEL: +81-3-3527-1560, FAX: +81-3-5256-8500
Shonan satellite office & laboratory
C33M-1110　Shonan Health Innovation Park
2-26-1, Muraokahigashi, Fujisawa-city, Kanagawa. 251-8555, Japan MAP
Factorysame as Head office
Employee
289（Production　165,R&D　37,QU　61）as of December, 2021
Current Certification Status
FDA Inspections:
  • 2000 JPP-Ⅰ
  • 2005 JPP-Ⅰ, JPP-Ⅱ
  • 2009 JPP-Ⅰ, JPP-Ⅱ
  • 2012 JPP-Ⅰ
  • 2016 JPP-Ⅰ, JPP-Ⅱ
  • 2018 JPP-Ⅰ, JPP-Ⅱ
  • 2019 JPP-Ⅰ, JPP-Ⅱ
KFDA(MFDS) Inspections:
  • 2007 JPP-Ⅰ
  • 2012 JPP-Ⅰ
AIFA Inspections:
  • 2012 JPP-Ⅰ
ISO14001:
  • 2001

Milestones

60 years of History

While the out-sourcings at each level of intermediates, APIs and preparations are aggressively and strategically deployed by pharmaceutical companies, we are confident of exactly responding to the demand of out-sourcing at any stage from new drug development to the drug already on the market with making the most of our experiences and know-how accumulated as a "Composer" in contract manufacturing of API or key intermediates.

1950s
1950
  • ・Established for the production of anti-histamines
1955
  • ・Production of Monochloroacetic acid started to proceed to industrial chemicals
1960s
1961
  • ・Production of intermediates for Vitamin B1 and B2 started
1970s
1976
  • ・Production of intermediates for Sulfa Drugs started
1980s
1983
  • ・Production of Malonic acid esters by CO process started at Omi factory
1986
  • ・Multi-purpose plant for intermediates for drug established
  • ・Received FDA inspection
1989
  • ・Started contract manufacturing of intermediates for an anti-bacterial
1990s
1996
  • ・Awarded certificate of approval ISO 9002(returned in 2002, integrated with GMP system)
1998
  • ・JPP-Ⅰ ,GMP compliance plant for APIs completed
2000s
2000
  • ・Received FDA inspection at JPP-Ⅰ
  • ・JHP renewed with ultra-low temperature reaction equipment introduced
2001
  • ・JPP-Ⅱ altered to comply with GMP
  • ・Awarded certificate of approval ISO 14001
2002
  • ・JPP-Ⅰ, production capacity enhanced
2004
  • ・JHP, production capacity enhanced
  • ・Analytical Research Center newly established
2005
  • ・Received FDA inspection at JPP-Ⅰ & JPP-Ⅱ
2006
  • ・JPP-Ⅰ, production capacity enhanced
2007
  • ・Received KFDA(MFDS) inspection at JPP-Ⅰ
2008
  • ・JPP-Ⅱ, production capacity enhanced
2009
  • ・Received FDA inspection at JPP-Ⅰ & JPP-Ⅱ
2010s
2012
  • ・Received FDA inspection at JPP-Ⅰ
  • ・Received KFDA(MFDS) inspection at JPP-Ⅰ
  • ・Received AIFA inspection at JPP-Ⅰ
2013
  • ・Research and Development Center newly established
2015
  • ・JPP-Ⅲ, a plant to cope with Highly Potent Activity completed
2016
  • ・Received FDA inspection at JPP-Ⅰ & JPP-Ⅱ
2018
  • ・Received FDA inspection at JPP-Ⅰ & JPP-Ⅱ
2019
  • ・Received FDA inspection at JPP-Ⅰ & JPP-Ⅱ
CATEGORY
PAGE TOP